Drugs / CY
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06342986 Background | Jul 2024 → Mar 2026 overdue | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Masonic Cancer Center, University of Minnesota | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CY | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06342986 ↗ |
| Route | Intravenous | “CY 300 mg/m2 IV given on day -4.” NCT06342986 ↗ |